News Beyfortus now has a direct rival after FDA OK for Enflonsia MSD could soon enter the US market for drugs used to protect infants from RSV infections, setting up a rivalry with AstraZeneca/Sanofi's Beyfortus.
News Sanofi starts shipping RSV drug early as rival nears market As an FDA decision nears from a rival MSD drug, Sanofi is speeding up the rollout of RSV antibody Beyfortus to get ahead of this year's season.
News ASCO 25: Sanofi hopes on-body delivery will boost Sarclisa Can a new on-body injector version of Sanofi's Sarclisa help it claim market share from J&J's rival top-selling Darzalex in multiple myeloma?
News Sanofi draws up $9.1bn plan to buy Blueprint Meds Sanofi has bolstered its rare disease business with an agreement to buy Blueprint Medicines and blockbuster-in-waiting Ayvakit for ASM.
News Sanofi admits giving free Olympics tickets to patients Despite a voluntary admission of a breach of the ABPI code, Sanofi is deemed to have "brought discredit" on the pharma industry.
Patients The need for a science-first mindset: The vaccine landscape ... In a new pharmaphorum podcast, Rebecca Catterick, previously at Sanofi, discusses the decline in vaccination rates.
R&D Precision, speed, impact: Evolving mass spectrometry for med... MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face